已收盘 06-05 16:00:00 美东时间
-0.010
-0.61%
HCW Biologics Inc. (the "Company") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing first-in-class fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia, today
05-27 19:47
HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune, cancer and senescence-associated
05-21 21:56
HCW Biologics shares soared Friday after the company reported stronger quarterly results, advanced a key licensing deal and reaffirmed upcoming autoimmune clinical data milestones despite ongoing going-concern risks.
05-16 01:35
US stocks down, S&P 500 falls 1%; Dow down 1.08%, NASDAQ down 1.42%. Energy shares up 1.5%; materials stocks down 2.1%. RBC Bearings beats Q1 estimates.
05-16 00:17
Dow Jones falls 500 points, S&P drops 1.29%, NASDAQ down 1.79%. Energy shares rise 1.2%, tech stocks fall 2.2%. NY Empire State Manufacturing Index at 19.6.
05-15 21:57
HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link
03-02 21:14
HCW Biologics and WY Biotech have inked a deal with HCW receiving a $7 million upfront payment for its technology transfer. Additional milestone payments and royalties are also potential. HCW retains an option to recapture rights for the Americas post a Phase 1 trial, while WY Biotech handles global development costs.
2025-06-04 12:20
北京时间2025年02月04日03时33分,康乃德生物(CNTB.us)股票出现异动,股价快速拉升7.00%。截至发稿,该股报1.040美元/股,成交量2.2915万股,换手率0.04%,振幅7.20%。 最近的财报数据显示,该股实现营业收入24.12百万美元,净利润7.65百万美元,每股收益0.14美元,毛利23.64百万美元,市盈率-2.67倍。 机构评级方面,在所有1家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。 康乃德生物股票所在的生物技术行业中,整体跌幅为0.21%。其相关个股中,Hcw Biologics Inc.、Invivyd, Inc.、Gh Re...
2025-02-04 03:33
北京时间2024年11月19日02时44分,Editas Medicine, Inc.(EDIT.us)股票出现异动,股价急速下跌5.08%。截至发稿,该股报2.53美元/股,成交量113.718万股,换手率1.38%,振幅6.02%。 最近的财报数据显示,该股实现营业收入61000.00美元,净利润-62.14百万美元,每股收益-0.75美元,毛利-1.54百万美元,市盈率-1.00倍。 机构评级方面,在所有18家参与评级的机构中,56%的券商给予买入建议,44%的券商给予持有建议,无券商给予卖出建议。 Editas Medicine, Inc.股票所在的生物技术行业中,整体涨幅为0.09%...
2024-11-19 02:44
北京时间2024年10月09日01时25分,Allogene Therapeutics, Inc.(ALLO.us)股票出现波动,股价快速拉升5.00%。截至发稿,该股报2.71美元/股,成交量70.9175万股,换手率0.34%,振幅5.23%。 最近的财报数据显示,该股实现营业收入0.00美元,净利润-66.36百万美元,每股收益-0.35美元,毛利-3.64百万美元,市盈率-1.70倍。 机构评级方面,在所有18家参与评级的机构中,72%的券商给予买入建议,28%的券商给予持有建议,无券商给予卖出建议。 Allogene Therapeutics, Inc.股票所在的生物技术行业中,整体...
2024-10-09 01:25